Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Betta Pharma Stock Purchase Agreement	At-The-Market Equity Program	Underwritten Offering	Common Stock	Common Stock Betta Pharma Stock Purchase Agreement	Common Stock At-The-Market Equity Program	Common Stock Underwritten Offering	Additional Paid-In Capital	Additional Paid-In Capital Betta Pharma Stock Purchase Agreement	Additional Paid-In Capital At-The-Market Equity Program	Additional Paid-In Capital Underwritten Offering	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2023					60,467,188
Beginning balance at Dec. 31, 2023	$ 246,114				$ 6				$ 774,618				$ (127)	$ (528,383)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock, net (in shares)						5,567,928	4,132,122
Issuance of common stock, net		$ 20,000	$ 24,370			$ 1				$ 19,999	$ 24,370
Exercise of stock options and release of stock units (in shares)					149,818
Exercise of stock options and release of stock units	778								778
Issuance of common stock upon vesting of restricted stock units, net of shares repurchased for tax withholding (in shares)					176,819
Issuance of common stock upon vesting of restricted stock units, net of shares repurchased for tax withholding	(194)								(194)
Issuance of common stock under the 2020 ESPP (in shares)					110,895
Issuance of common stock under the 2020 ESPP	382								382
Stock-based compensation	29,662								29,662
Unrealized gain (loss) on marketable securities	180												180
Net loss	(105,316)													(105,316)
Other (in shares)					21,129
Other	10								10
Ending balance (in shares) at Dec. 31, 2024					70,625,899
Ending balance at Dec. 31, 2024	215,986				$ 7				849,625				53	(633,699)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock, net (in shares)							3,769,483	21,895,000
Issuance of common stock, net			$ 9,340	$ 116,869				$ 2			$ 9,340	$ 116,867
Exercise of stock options and release of stock units (in shares)					50,000
Exercise of stock options and release of stock units	107								107
Issuance of common stock upon vesting of restricted stock units, net of shares repurchased for tax withholding (in shares)					349,766
Issuance of common stock upon vesting of restricted stock units, net of shares repurchased for tax withholding	(193)								(193)
Issuance of common stock under the 2020 ESPP (in shares)					170,703
Issuance of common stock under the 2020 ESPP	273								273
Stock-based compensation	19,099								19,099
Unrealized gain (loss) on marketable securities	(3)												(3)
Net loss	(104,994)													(104,994)
Other (in shares)					53,567
Other	103								103
Ending balance (in shares) at Dec. 31, 2025					96,914,418
Ending balance at Dec. 31, 2025	$ 256,587				$ 9				$ 995,221				$ 50	$ (738,693)